Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Ekso Bionics Holdings (EKSO) EBITDA (2016 - 2025)

Historic EBITDA for Ekso Bionics Holdings (EKSO) over the last 14 years, with Q3 2025 value amounting to -$1.4 million.

  • Ekso Bionics Holdings' EBITDA rose 4467.1% to -$1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.1 million, marking a year-over-year increase of 595.68%. This contributed to the annual value of -$10.5 million for FY2024, which is 3252.8% up from last year.
  • Ekso Bionics Holdings' EBITDA amounted to -$1.4 million in Q3 2025, which was up 4467.1% from -$3.8 million recorded in Q2 2025.
  • Ekso Bionics Holdings' 5-year EBITDA high stood at -$1.4 million for Q2 2021, and its period low was -$4.6 million during Q1 2023.
  • Moreover, its 5-year median value for EBITDA was -$3.1 million (2024), whereas its average is -$3.1 million.
  • Examining YoY changes over the last 5 years, Ekso Bionics Holdings' EBITDA showed a top increase of 8831.1% in 2021 and a maximum decrease of 18330.88% in 2021.
  • Over the past 5 years, Ekso Bionics Holdings' EBITDA (Quarter) stood at -$2.6 million in 2021, then crashed by 55.69% to -$4.1 million in 2022, then rose by 7.56% to -$3.8 million in 2023, then surged by 34.9% to -$2.5 million in 2024, then soared by 41.73% to -$1.4 million in 2025.
  • Its EBITDA was -$1.4 million in Q3 2025, compared to -$3.8 million in Q2 2025 and -$3.4 million in Q1 2025.